{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:08:52Z","timestamp":1785834532537,"version":"3.56.0"},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is a major cause of\ndeath amongst tuberculosis patients. Nanomedicine avoids some limitations of conventional drug treatment\nand increases therapeutic efficacy against bacterial infections. However, the effect of anti-TB drug\nnanoparticle (NP) compounds in anti-TB regimens against MDR-TB remains unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The objective of this article is to prepare levofloxacin, linezolid, ethambutol, prothionamide,\nand pyrazinamide encapsulated NPs and to evaluate their therapeutic efficacy against MDR-TB in macrophages.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Drug-loaded PLGA NPs were prepared by the multiple emulsion method. The colocalization,\nintracellular release, and anti-TB activity of these NPs were investigated on cultured macrophages. The\nimmune phenotype of the macrophages, including their mitochondrial membrane potential, reactive\noxygen species (ROS), and nitric oxide (NO) production, was evaluated following treatment with NPs\nor free drug compounds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>All drug-loaded PLGA NPs were spherical in shape, 150 to 210 nm in size, and showed\n14.22% to 43.51% encapsulation efficiencies and long-duration release. Drug-loaded PLGA NPs were\nmainly distributed in the cytoplasm of macrophages, showed high cellular compatibility, and maintained\ntheir concentration for at least 13 days. Compared with the free drug compounds, the number of colonies\nafter exposure to PLGA NP compounds was significantly less. The enhanced antibacterial activity\nof the NP compounds may be due to the enhanced levels of ROS and NO and the increased early apoptosis\nstress within M. tuberculosis-infected macrophages additionally.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The application of PLGA NP compounds not only enhances drug efficacy but also induces\ninnate bactericidal events in macrophages, confirming this as a promising approach for MDR-TB therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201819666220511120215","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:14:28Z","timestamp":1652332468000},"page":"306-316","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles\nEncapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid,\nor Ethambutol on Multidrug-Resistant Mycobacterium tuberculosis"],"prefix":"10.2174","volume":"20","author":[{"given":"Jiangping","family":"Xu","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nGuangzhou Chest Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjian","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nGuangzhou Chest Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Niu","sequence":"additional","affiliation":[{"name":"Pulmonary Disease Institute, Guangzhou Chest Hospital, Guangzhou,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2020","unstructured":"Global tuberculosis report: Executive summary WHOAvailable from: 2020","journal-title":"Global tuberculosis report: Executive summary"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/1567201814666171120125916","volume":"15","author":"Singh G.","year":"2018","unstructured":"Singh G.; Kesharwani P.; Srivastava A.K.; Tuberculosis treated by multiple drugs: An overview. Curr Drug Deliv 2018,15(3),312-320","journal-title":"Curr Drug Deliv"},{"key":"ref=3","year":"2019","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment WHOAvailable from: 2019","journal-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","volume":"18","author":"Tiberi S.","year":"2018","unstructured":"Tiberi S.; du Plessis N.; Walzl G.; Vjecha M.J.; Rao M.; Ntoumi F.; Mfinanga S.; Kapata N.; Mwaba P.; McHugh T.D.; Ippolito G.; Migliori G.B.; Maeurer M.J.; Zumla A.; Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018,18(7),e183-e198","journal-title":"Lancet Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2174\/1567201816666190201144815","volume":"16","author":"Hussain A.","year":"2019","unstructured":"Hussain A.; Singh S.; Das S.S.; Anjireddy K.; Karpagam S.; Shakeel F.; Nanomedicines as drug delivery carriers of anti-tubercular drugs: From pathogenesis to infection control. Curr Drug Deliv 2019,16(5),400-429","journal-title":"Curr Drug Deliv"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","volume":"62","author":"Sosnik A.","year":"2010","unstructured":"Sosnik A.; Carcaboso A.M.; Glisoni R.J.; Moretton M.A.; Chiappetta D.A.; New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010,62(4-5),547-559","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2174\/1567201818666210212092112","volume":"18","author":"H&#xE4;drich G.","year":"2021","unstructured":"H&#xE4;drich G.; Vaz G.R.; Boschero R.; Appel A.S.; Ramos C.; Halicki P.C.B.; Bidone J.; Teixeira H.F.; Muccillo-Baisch A.L.; Dal-B&#xF3; A.; Silva Pinto L.; Dailey L-A.; Da Silva P.E.A.; Ramos D.F.; Dora C.L.; Development of lipid nanocarriers for tuberculosis treatment: Evaluation of suitable excipients and nanocarriers. Curr Drug Deliv 2021,18(6),770-778","journal-title":"Curr Drug Deliv"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/jps.23857","volume":"103","author":"Kaur G.","year":"2014","unstructured":"Kaur G.; Mehta S.K.; Probing location of anti-TB drugs loaded in Brij 96 microemulsions using thermoanalytical and photophysical approach. J Pharm Sci 2014,103(3),937-944","journal-title":"J Pharm Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41579-020-0420-1","volume":"19","author":"Makabenta J.M.V.","year":"2021","unstructured":"Makabenta J.M.V.; Nabawy A.; Li C.H.; Schmidt-Malan S.; Patel R.; Rotello V.M.; Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol 2021,19(1),23-36","journal-title":"Nat Rev Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2017.09.003","volume":"22","author":"Dallenga T.","year":"2017","unstructured":"Dallenga T.; Repnik U.; Corleis B.; Eich J.; Reimer R.; Griffiths G.W.; Schaible U.E.; M. tuberculosis-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages. Cell Host Microbe 2017,22(4),519-530.e3","journal-title":"Cell Host Microbe"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","volume":"60","author":"Sturkenboom M.G.G.","year":"2021","unstructured":"Sturkenboom M.G.G.; M&#xE4;rtson A.G.; Svensson E.M.; Sloan D.J.; Dooley K.E.; van den Elsen S.H.J.; Denti P.; Peloquin C.A.; Aarnoutse R.E.; Alffenaar J.C.; Population pharmacokinetics and bayesian dose adjustment to advance TDM of anti-TB drugs. Clin Pharmacokinet 2021,60(6),685-710","journal-title":"Clin Pharmacokinet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s11095-017-2206-3","volume":"34","author":"Upadhyay S.","year":"2017","unstructured":"Upadhyay S.; Khan I.; Gothwal A.; Pachouri P.K.; Bhaskar N.; Gupta U.D.; Chauhan D.S.; Gupta U.; Conjugated and entrapped HPMA-PLA Nano-polymeric micelles based dual delivery of first line anti TB drugs: Improved and safe drug delivery against sensitive and resistant Mycobacterium tuberculosis. Pharm Res 2017,34(9),1944-1955","journal-title":"Pharm Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.addr.2013.07.011","volume":"65","author":"Pelgrift R.Y.","year":"2013","unstructured":"Pelgrift R.Y.; Friedman A.J.; Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 2013,65(13-14),1803-1815","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.2147\/IJN.S34341","volume":"7","author":"Abdelghany S.M.","year":"2012","unstructured":"Abdelghany S.M.; Quinn D.J.; Ingram R.J.; Gilmore B.F.; Donnelly R.F.; Taggart C.C.; Scott C.J.; Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomedicine 2012,7,4053-4063","journal-title":"Int J Nanomedicine"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1128\/AEM.06513-11","volume":"78","author":"Brown A.N.","year":"2012","unstructured":"Brown A.N.; Smith K.; Samuels T.A.; Lu J.; Obare S.O.; Scott M.E.; Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol 2012,78(8),2768-2774","journal-title":"Appl Environ Microbiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1021\/acsinfecdis.9b00134","volume":"5","author":"Li C.H.","year":"2019","unstructured":"Li C.H.; Chen X.; Landis R.F.; Geng Y.; Makabenta J.M.; Lemnios W.; Gupta A.; Rotello V.M.; Phytochemical-based nanocomposites for the treatment of bacterial biofilms. ACS Infect Dis 2019,5(9),1590-1596","journal-title":"ACS Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1096\/fj.04-2747rev","volume":"19","author":"Moghimi S.M.","year":"2005","unstructured":"Moghimi S.M.; Hunter A.C.; Murray J.C.; Nanomedicine: Current status and future prospects. FASEB J 2005,19(3),311-330","journal-title":"FASEB J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkg477","volume":"52","author":"Pandey R.","year":"2003","unstructured":"Pandey R.; Sharma A.; Zahoor A.; Sharma S.; Khuller G.K.; Prasad B.; Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003,52(6),981-986","journal-title":"J Antimicrob Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2174\/092986710790416290","volume":"17","author":"Zhang L.","year":"2010","unstructured":"Zhang L.; Pornpattananangku D.; Hu C.M.J.; Huang C.M.; Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010,17(6),585-594","journal-title":"Curr Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1128\/AAC.00354-15","volume":"59","author":"Park S.I.","year":"2015","unstructured":"Park S.I.; Oh J.; Jang K.; Yoon J.; Moon S.J.; Park J.S.; Lee J.H.; Song J.; Jang I.J.; Yu K.S.; Chung J.Y.; Pharmacokinetics of second-line antituberculosis drugs after multiple administrations in healthy volunteers. Antimicrob Agents Chemother 2015,59(8),4429-4435","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","year":"2017","unstructured":"Guidelines for treatment of drug-susceptible tuberculosis and patient care WHOAvailable from: 2017","journal-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.tube.2003.07.001","volume":"83","author":"Pandey R.","year":"2003","unstructured":"Pandey R.; Zahoor A.; Sharma S.; Khuller G.K.; Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003,83(6),373-378","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1128\/AAC.41.5.1004","volume":"41","author":"Collins L.","year":"1997","unstructured":"Collins L.; Franzblau S.G.; Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997,41(5),1004-1009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","volume":"144","author":"Patel S.","year":"2019","unstructured":"Patel S.; Kim J.; Herrera M.; Mukherjee A.; Kabanov A.V.; Sahay G.; Brief update on endocytosis of nanomedicines. Adv Drug Deliv Rev 2019,144,90-111","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1242\/jcs.121814","volume":"126","author":"Kalluru R.","year":"2013","unstructured":"Kalluru R.; Fenaroli F.; Westmoreland D.; Ulanova L.; Maleki A.; Roos N.; Paulsen Madsen M.; Koster G.; Egge-Jacobsen W.; Wilson S.; Roberg-Larsen H.; Khuller G.K.; Singh A.; Nystr&#xF6;m B.; Griffiths G.; Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci 2013,126(Pt 14),3043-3054","journal-title":"J Cell Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.colsurfb.2009.10.036","volume":"76","author":"Onoshita T.","year":"2010","unstructured":"Onoshita T.; Shimizu Y.; Yamaya N.; Miyazaki M.; Yokoyama M.; Fujiwara N.; Nakajima T.; Makino K.; Terada H.; Haga M.; The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf B Biointerfaces 2010,76(1),151-157","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2015.06.005","volume":"211","author":"Lemmer Y.","year":"2015","unstructured":"Lemmer Y.; Kalombo L.; Pietersen R.D.; Jones A.T.; Semete-Makokotlela B.; Van Wyngaardt S.; Ramalapa B.; Stoltz A.C.; Baker B.; Verschoor J.A.; Swai H.S.; de Chastellier C.; Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis. J Control Release 2015,211(1),94-104","journal-title":"J Control Release"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1021\/acs.biomac.9b00214","volume":"20","author":"Trousil J.","year":"2019","unstructured":"Trousil J.; Syrov&#xE1; Z.; Dal N.K.; Rak D.; Konefa\u0142 R.; Pavlova E.; Mat&#x11B;jkov&#xE1; J.; Cmarko D.; Kub&#xED;&#x10D;kov&#xE1; P.; Pavli\u0161 O.; Urb&#xE1;nek T.; Sedl&#xE1;k M.; Fenaroli F.; Ra\u0161ka I.; \u0160t&#x11B;p&#xE1;nek P.; Hrub&#xFD; M.; Rifampicin nanoformulation enhances treatment of tuberculosis in zebrafish. Biomacromolecules 2019,20(4),1798-1815","journal-title":"Biomacromolecules"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.smim.2014.10.001","volume":"26","author":"Moraco A.H.","year":"2014","unstructured":"Moraco A.H.; Kornfeld H.; Cell death and autophagy in tuberculosis. Semin Immunol 2014,26(6),497-511","journal-title":"Semin Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/iai.65.1.298-304.1997","volume":"65","author":"Keane J.","year":"1997","unstructured":"Keane J.; Balcewicz-Sablinska M.K.; Remold H.G.; Chupp G.L.; Meek B.B.; Fenton M.J.; Kornfeld H.; Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997,65(1),298-304","journal-title":"Infect Immun"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.4049\/jimmunol.161.5.2636","volume":"161","author":"Balcewicz-Sablinska M.K.","year":"1998","unstructured":"Balcewicz-Sablinska M.K.; Keane J.; Kornfeld H.; Remold H.G.; Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998,161(5),2636-2641","journal-title":"J Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.chom.2012.03.008","volume":"11","author":"Kim J.J.","year":"2012","unstructured":"Kim J.J.; Lee H-M.; Shin D.M.; Kim W.; Yuk J-M.; Jin H.S.; Lee S.H.; Cha G.H.; Kim J.M.; Lee Z.W.; Shin S.J.; Yoo H.; Park Y.K.; Park J.B.; Chung J.; Yoshimori T.; Jo E.K.; Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe 2012,11(5),457-468","journal-title":"Cell Host Microbe"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2249.1990.tb06454.x","volume":"80","author":"Sibley L.D.","year":"1990","unstructured":"Sibley L.D.; Adams L.B.; Krahenbuhl J.L.; Inhibition of interferon-gamma-mediated activation in mouse macrophages treated with lipoarabinomannan. Clin Exp Immunol 1990,80(1),141-148","journal-title":"Clin Exp Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1126\/science.1092873","volume":"302","author":"Pieters J.","year":"2003","unstructured":"Pieters J.; Ploegh H.; Microbiology. Chemical warfare and mycobacterial defense. Science 2003,302(5652),1900-1902","journal-title":"Science"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.bi.63.070194.001135","volume":"63","author":"Bredt D.S.","year":"1994","unstructured":"Bredt D.S.; Snyder S.H.; Nitric oxide: A physiologic messenger molecule. Annu Rev Biochem 1994,63(1),175-195","journal-title":"Annu Rev Biochem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1128\/IAI.68.3.1231-1234.2000","volume":"68","author":"Cooper A.M.","year":"2000","unstructured":"Cooper A.M.; Segal B.H.; Frank A.A.; Holland S.M.; Orme I.M.; Transient loss of resistance to pulmonary tuberculosis in p47(phox-\/-) mice. Infect Immun 2000,68(3),1231-1234","journal-title":"Infect Immun"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cell.2004.11.038","volume":"119","author":"Gutierrez M.G.","year":"2004","unstructured":"Gutierrez M.G.; Master S.S.; Singh S.B.; Taylor G.A.; Colombo M.I.; Deretic V.; Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004,119(6),753-766","journal-title":"Cell"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1126\/science.1129577","volume":"313","author":"Singh S.B.","year":"2006","unstructured":"Singh S.B.; Davis A.S.; Taylor G.A.; Deretic V.; Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006,313(5792),1438-1441","journal-title":"Science"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2011.10.006","volume":"24","author":"Deretic V.","year":"2012","unstructured":"Deretic V.; Autophagy as an innate immunity paradigm: Expanding the scope and repertoire of pattern recognition receptors. Curr Opin Immunol 2012,24(1),21-31","journal-title":"Curr Opin Immunol"},{"key":"ref=40","first-page":"278","volume":"64","author":"Jain S.K.","year":"2010","unstructured":"Jain S.K.; Gupta Y.; Ramalingam L.; Jain A.; Jain A.; Khare P.; Bhargava D.; Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J Pharm Sci Technol 2010,64(3),278-287","journal-title":"PDA J Pharm Sci Technol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1600-065X.2007.00547.x","volume":"219","author":"Rohde K.","year":"2007","unstructured":"Rohde K.; Yates R.M.; Purdy G.E.; Russell D.G.; Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev 2007,219(1),37-54","journal-title":"Immunol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.cellbio.20.010403.114015","volume":"20","author":"Vergne I.","year":"2004","unstructured":"Vergne I.; Chua J.; Singh S.B.; Deretic V.; Cell biology of Mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol 2004,20(1),367-394","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"a016980","DOI":"10.1101\/cshperspect.a016980","volume":"5","author":"Akinc A.","year":"2013","unstructured":"Akinc A.; Battaglia G.; Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol 2013,5(11),a016980","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220511120215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204577\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220511120215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:45:02Z","timestamp":1676533502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204577\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220511120215","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}